Company UpdateNewspaper Publication
Specialty Chemicals
Titan Biotech Ltd
Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 40 filings·Updated 14 Aug 2026
Showing 10 of 40 filings.
14 Aug 20261 filing
6 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Dematerialisation processing confirmed, securities listed, and owner details updated within 15 days
Dematerialisation status
- Dematerialisation requests were confirmed to the depositories (accepted or rejected).
- Dematerialised securities were listed on stock exchanges where the earlier issues are listed.
- Physical certificates for dematerialisation were mutilated and cancelled; the registered owner updated within 15 days.
25 Jun 20261 filing
Company UpdatePress Release / Media Release (Revised)
Titan Biotech reports loss of share certificate; IEPF duplicate issuance for 300 shares
Share certificate loss update
- Titan Biotech reports loss of share certificate(s) under Regulation 39(3).
- Shareholder details: Dhiren B Sanghvi and Prashant K Shah; Folio 0014196; Cert Nos 34517–34519.
- Distinctive Nos 3432171-3432470; No. of shares: 300.
- Shares were previously transferred to IEPF; now claimed by investor(s).
- Advertisement published 25-Jun-2026; objections due within 15 days.
- If no objections, duplicate issue will be processed through IEPF.
- RTA: Beetal Financial & Computer Services Pvt. Ltd.; Company Secretary: Charanjit Singh.
- Please host records on BSE website.
1 Jun 20261 filing
Company UpdateNewspaper Publication
Newspaper publication of the Audited Financial Results (Standalone & Consolidated) for fourth quarter and year ended March 31, 2026
6 May 20261 filing
Company UpdatePress Release / Media Release
Titan Biotech Ltd - 524717 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Special window
- Company informed shareholders about a one-year special window for transfer request re-lodgement and dematerialisation.
Re-lodgement period
- The window runs from February 5, 2026 to February 4, 2027.
Publication
- Notice was published in Financial Express and Naya India on May 6, 2026.
4 May 20261 filing
Company UpdateReg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the financial year ending March 31, 2026
26 Mar 20261 filing
Insider Trading / SASTClosure of Trading Window
Closure of Trading Window
27 Feb 20261 filing
Company UpdateGeneral
Intimation pertaining to credit confirmation of Equity Shares from the depositories regarding Sub-Division/Split of Equity Shares of the Company.
17 Feb 20261 filing
Company UpdateGeneral
Please find attached herewith report for the period from 01.01.2026 to 06.01.2026 pertaining to re-lodgment of transfer of physical shares
12 Feb 20261 filing
ResultFinancial Results
Titan Biotech Ltd - 524717 - Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31, 2025
Standalone Financial Performance Q3 & 9M FY26
- Revenue from operations rose 4.0% QoQ to Rs 5,650.57 lakhs in Q3 FY26
- 9M FY26 revenue increased 29.8% YoY to Rs 15,735.68 lakhs
- Total income for Q3 FY26 was Rs 5,776.28 lakhs, up 3.7% QoQ
- 9M FY26 total income grew 29.8% YoY to Rs 16,066.06 lakhs
- Cost of materials consumed was Rs 2,727.66 lakhs in Q3 FY26, flat QoQ
- Employee benefits expense increased 15.5% QoQ to Rs 853.09 lakhs in Q3 FY26
- Finance costs rose to Rs 25.74 lakhs in Q3 FY26 from Rs 22.41 lakhs in Q2
- EBITDA (PBT before tax and exceptional) was Rs 1,056.21 lakhs in Q3 FY26, up 14.6% QoQ
- Profit before tax grew 14.6% QoQ to Rs 1,056.21 lakhs in Q3 FY26
- Profit after tax increased 14.6% QoQ to Rs 786.82 lakhs in Q3 FY26
- Basic and diluted EPS for Q3 FY26 stood at Rs 9.52 per share
- Total comprehensive income for Q3 FY26 was Rs 788.65 lakhs
- Company recognized income tax provision under section 115BAA of Income Tax Act
Consolidated Financial Performance Q3 & 9M FY26
- Consolidated revenue from operations was Rs 5,772.66 lakhs in Q3 FY26
- 9M FY26 consolidated revenue increased to Rs 15,735.67 lakhs
- Consolidated profit before tax was Rs 1,057.4 lakhs in Q3 FY26
- Consolidated profit after tax was Rs 852.86 lakhs in Q3 FY26
- Group share of profit from associates was Rs 66.04 lakhs in Q3 FY26
- Basic and diluted EPS on consolidated basis was Rs 10.32 per share in Q3 FY26
- Total comprehensive income on consolidated basis was Rs 854.6 lakhs in Q3 FY26
Audit and Compliance
- Standalone and consolidated Q3 & 9M FY26 results reviewed by Audit Committee
- Limited review reports issued by statutory auditors with unmodified conclusion
- Financials prepared as per Ind AS 34 and Companies Act 2013
- Freight included in revenue and other expenses to neutralize impact in current year
Showing 10 of 40 filings